Credit Suisse Starts Aimmune Therapeutics (AIMT) at Outperform

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. SWKS
7. ANET
8. SPY
9. XYZ
10. CVS

Go back to Credit Suisse Starts Aimmune Therapeutics (AIMT) at Outperform

BofA/Merrill Lynch Starts Aimmune Therapeutics (AIMT) at Buy

August 31, 2015 7:43 AM EDT

BofA/Merrill Lynch initiated coverage on Aimmune Therapeutics (NASDAQ: AIMT) with a Buy rating and a price target of $36.00.

For an analyst ratings summary and ratings history on Aimmune Therapeutics click here. For more ratings news on Aimmune Therapeutics click here.

Shares of Aimmune Therapeutics closed at $21.11 yesterday.

... More

Piper Jaffray Starts Aimmune Therapeutics (AIMT) at Overweight

August 31, 2015 6:27 AM EDT

Piper Jaffray initiates coverage on Aimmune Therapeutics (NASDAQ: AIMT) with a Overweight rating and a price target of $35.00, leading data in peanut allergy.

Analyst Charles Duncan commented, "Aimmune is leveraging its broadly applicable oral immunotherapy (OIT) platform to develop proprietary products aimed at protecting patients... More